Home > Cardiology > AHA 2023 > Edoxaban versus warfarin in CTEPH

Edoxaban versus warfarin in CTEPH

Presented by
Dr Kazuya Hosokawa, Kyushu University, Japan
AHA 2023
Phase 3, KABUKI
In patients with chronic thromboembolic pulmonary hypertension (CTEPH) who had received a re-perfusion treatment, edoxaban showed non-inferiority to warfarin for preventing the worsening of pulmonary haemodynamics. Also, symptomatic venous thromboembolism (VTE) and bleeding rates were comparably low in edoxaban receivers and in warfarin-treated patients.

The multicentre, single-blind, non-inferiority, warfarin-controlled, phase 3 KABUKI trial (NCT04730037) compared edoxaban with warfarin in patients with CTEPH (n=74). Participants were randomised 1:1 and the primary endpoint was the ratio of week 48 pulmonary vascular resistance (PVR) to baseline PVR. Dr Kazuya Hosokawa (Kyushu University, Japan) presented the results [1].

The PVR ratio was numerically in favour of edoxaban (treatment effect 0.92; 95% CI 0.82–1.03), reaching the non-inferiority threshold, which was an upper limit of the confidence interval of 1.19 (Pnon-inferiority<0.001). Clinically relevant bleeding occurred in 2.7% of the edoxaban-treated patients and in 5.4% of the warfarin-treated patients (P=1.00). Finally, 1 serious adverse event (AE) was observed in the edoxaban arm, a case of worsening pulmonary hypertension, and 3 serious AEs were reported in the warfarin arm, being 1 tooth extraction, a haemorrhagic duodenal ulcer, and a case of urothelial transitional cell carcinoma.

  1. Hosokawa K, et al. A multicenter, randomised, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial. FS07, AHA Scientific Sessions 2023, 10–12 November, Philadelphia, PA, USA.


Medical writing support was provided by Robert van den Heuvel.

Copyright ©2023 Medicom Medical Publishers

Posted on